Literature DB >> 9031103

Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG.

T Haferlach1, J M Bennett, H Löffler, W Gassmann, J W Andersen, N Tuzuner, P A Casslleth, C Fonatsch, C Schoch, B Schlegelberger, R Becher, E Thiel, W D Ludwig, M C Sauerland, A Heinecke, T Büchner.   

Abstract

The translocation t(8;21) is one of the most common structural aberrations in acute myeloid leukemia (AML). Excellent response rates and a better relapse-free survival have been described. We analyzed specific morphologic and cytochemical features including dysplasia and other prognostic factors in 41 patients with AML and t(8;21) who underwent aggressive chemotherapy in two national cooperative group studies. Five patients were classified as AML M1 and 36 as AML M2 according to the FAB criteria. Auer rods were detected in 28 patients (68%), however in only 16 patients were they "thin and elongated" as has been described as typical for t(8;21). The presence or absence of Auer rods did not appear to be associated with disease-free survival in this sample. Dysgranulopoiesis was detected in 31/41 patients (90%); five of these patients additionally had dyserythropoiesis (12%). In six cases (15%), dysmegakaryopoiesis was seen in combination with dysgranulopoiesis. Only one patient had trilineage dysplasia. Dysplastic features had no influence on prognosis. Additional cytogenetic abnormalities were detected in 24/41 patients. Twelve male (48%) and four female (25%) had a loss of a sex chromosome. This was correlated with a better disease-free survival (p = 0.039). The complete remission rate (CR) to chemotherapy was 90%. The early death rate was 10%. Disease-free survival of the complete responders was 60% at two years with no relapses observed in ten patients with 2-6 years of follow up. This favorable disease-free survival was observed with a variety of post-induction regimens and t(8;21) had been detected as an independent factor for good prognosis. The need for very intensive therapy, such as bone marrow transplantation, is unanswered at this time.

Entities:  

Mesh:

Year:  1996        PMID: 9031103     DOI: 10.3109/10428199609054825

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

1.  A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy.

Authors:  Anita Boyapati; Ming Yan; Luke F Peterson; Joseph R Biggs; Michelle M Le Beau; Dong-Er Zhang
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

Review 2.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 3.  Cytogenetics in acute myeloid leukemia.

Authors:  Claudia Schoch; Torsten Haferlach
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

4.  Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.

Authors:  Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

5.  Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia.

Authors:  Benjamin J Huang; Jenny L Smith; Jason E Farrar; Yi-Cheng Wang; Masayuki Umeda; Rhonda E Ries; Amanda R Leonti; Erin Crowgey; Scott N Furlan; Katherine Tarlock; Marcos Armendariz; Yanling Liu; Timothy I Shaw; Lisa Wei; Robert B Gerbing; Todd M Cooper; Alan S Gamis; Richard Aplenc; E Anders Kolb; Jeffrey Rubnitz; Jing Ma; Jeffery M Klco; Xiaotu Ma; Todd A Alonzo; Timothy Triche; Soheil Meshinchi
Journal:  Nat Commun       Date:  2022-09-19       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.